Navigation Links
Alexza Provides Pipeline Update
Date:7/31/2014

008 and AZ-009 may offer these two distinct patient populations an advantage over products available today." 

Alexza believes that there are potential advantages from the co-development of AZ-008 and AZ-009, as the two product candidates may be able to utilize the same preclinical and toxicology program, Investigational New Drug (IND) submission and initial Phase 1 clinical trial.  Beginning with planned Phase 2 clinical studies, Alexza expects to separate the two product candidates into distinct clinical development programs for the two different patient populations.

Alexza used a variety of tools in its new product identification process, including crowd-sourcing and traditional market research methods, and competitive and clinical analyses for each potential program.  The new product candidates will be based on the single dose Staccato platform that is currently being produced in Alexza's commercial production facility as ADASUVE®.

AZ-002 (Staccato alprazolam) for Acute Repetitive Seizures
Epilepsy, a disorder of recurrent seizures, affects approximately 2.5 million Americans, making it the third most common neurological disorder in the United States.  Acute repetitive seizures (ARS) refers to seizures that are serial, clustered, or crescendo, and ones that are distinct from the patient's usual seizure pattern.  ARS occurs in a subset of patients with epilepsy who regularly experience breakthrough seizures, despite treatment with a regular regimen of anti-epileptic drugs.

Among the implications of ARS are concerns for patient safety.  Prolonged or recurrent seizure activity persisting for 30 minutes or more may result in serious injury, health impacts or death, that correlate directly with seizure duration.  ARS, if left untreated, has been reported to evolve into a state of persistent seizure, or status epilepticus, which has
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
2. Alexza Receives Complete Response Letter for Adasuve™ NDA
3. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexza Pharmaceuticals Inc.
4. Alexza Announces Reverse Stock Split in Order to Maintain NASDAQ Listing
5. Alexza Secures a $20 Million Committed Equity Financing Facility with Azimuth Opportunity, L.P.
6. Alexza Announces Management Promotions
7. Alexza Reports 2012 Second Quarter Financial Results and Provides Business Update
8. Alexza Pharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference
9. Alexza Pharmaceuticals Corporate Presentation to Be Webcast at Three Upcoming Investor Conferences
10. Alexza to Report 2012 Year-End Financial Results on Tuesday, March 26, 2013
11. Peter W. Schineller Joins Alexza Pharmaceuticals as Senior Vice President and Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015  Delays in the launch and execution ... the decision-making process, resulting in missed opportunities and ... biopharmaceutical companies to develop a tactical approach to ... and more meaningful insights. According ... three-quarters of benchmarked study participants use review cycle ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Originally discovered by ... Yoshitomi Pharmaceutical Industries, Ltd) as an inflammatory drug, ... Senju Pharmaceutical Co., Ltd under the trade name ...
(Date:8/28/2015)... , Aug. 28, 2015 ... addition of the "Investigation Report on China,s Tobramycin ... Tobramycin is a traditional antibiotic whose eye drop and ... treatment of potential infection or inflammation caused by eye ... are able to produce tobramycin, among which ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2Investigation Report on China's Tobramycin Market, 2015-2019 2
... N.Y., Oct. 25, 2011 Misonix, Inc. (NASDAQ: ... that designs, manufactures and markets innovative therapeutic ultrasonic ... surgery, neurosurgery, laparoscopic surgery, and other surgical and ... the BoneScalpel™ Ultrasonic Bone Cutting System at the ...
... HIGHLIGHTS:2011 Results (all percentages are to comparable periods in 2010) ... to $626 million. Q3 sales grew organically by 4% with ... 4% and 2%, respectively.  Recently completed acquisitions contributed an additional ... additional 5% to reported sales growth in Q3. ...
Cached Medicine Technology:Misonix Exhibits BoneScalpel™ at the International Meeting on Advanced Spine Techniques 2Misonix Exhibits BoneScalpel™ at the International Meeting on Advanced Spine Techniques 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 2Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 4Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 5Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 6Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 7Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 8Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 9Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 10Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 11Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 12Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 13
(Date:8/28/2015)... MD (PRWEB) , ... August 28, 2015 , ... As ... system from Merz, received FDA clearance for results that last for two years, ... is exciting news for patients who are looking for a long-lasting, effective solution for ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... abuse, or those who might personally be struggling with chemical dependency, may be ... from Best Drug Rehabilitation, a results-driven holistic treatment center for addiction located in ...
(Date:8/28/2015)... ... August 28, 2015 , ... Altima Technologies, Inc., the maker ... data center assets and audio-video devices, recently released Visio Stencils for the following ... ProLiant Gen9, EMC VNX Series , Super Micro Computer SuperStorage, Hitachi Data Systems ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Nashville ... military veterans leading in business. Mr. Troy Mizell, Chairman of the Board ... Nashville Business Journal's 2015 Veterans Awards will recognize Nashville military veterans who, through ...
(Date:8/28/2015)... Arizona (PRWEB) , ... August 28, 2015 , ... ... and increased patient loyalty at a low cost. Personalized with practice contact information ... and existing patients. Dental offices can also incorporate Calendars into seasonal mailings, thank ...
Breaking Medicine News(10 mins):Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3Health News:MyGenetx Board Member Receives Veterans Award 2Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2
... Pa. , Jan. 27 CONNEXION Healthcare (CXHC) ... as Executive Vice President, Client Services. In this role, ... of CXHC, including its Clinical CONNEXION and Publication CONNEXION business ... of pharmaceutical marketing and sales experience.  Most recently, Rob served ...
... , DESTIN, Fla. , Jan. 27 Concordis ... today that Dr. K. Barton Farris has been appointed ... of this committee Dr. Farris will advise the company in its ... Trent Sommerville , Chairman and CEO of Concordis Group stated, "I ...
... ... , Jan. 27 Haiti is the poorest ... and other international relief agencies are there, they are mostly stationed where ... ( www.oiww.org ), located just outside Jacmel in the Southern Province, survived ...
... for Molecular Medicine and Therapeutics have uncovered a key ... disease, and identified a possible treatment for the disease. ... today and will appear in the January 28 edition ... is an inherited degenerative brain disease that causes cognitive ...
... PORTLAND, Ore.-- Adults with chronic rhinosinusitis a debilitating inflammation ... keeps coming back report significantly improved quality of ... a new study led by Oregon Health & Science ... issue of Otolaryngology Head and Neck Surgery ...
... ... supports on BetterBraces.com. , ... Diego, CA (PRWEB) January 22, 2010 -- DonJoy Velocity ankle braces were the ... total sales of Velocity ankle braces were double that of other ankle supports sold on ...
Cached Medicine News:Health News:Robert Naticchia Joins CONNEXION Healthcare as Executive Vice President, Client Services 2Health News:Concordis Group, Inc. Appoints Head of Physician Advisory Council 2Health News:Orphans International Worldwide Haiti Near Jacmel to Grow After Earthquake 2Health News:Orphans International Worldwide Haiti Near Jacmel to Grow After Earthquake 3Health News:Orphans International Worldwide Haiti Near Jacmel to Grow After Earthquake 4Health News:Orphans International Worldwide Haiti Near Jacmel to Grow After Earthquake 5Health News:Discovery of mechanism in brain cell injury in Huntington's offers new treatment approaches 2Health News:Surgery helps chronic sinusitis sufferers get relief 2Health News:DonJoy Velocity Ankle Brace is the Best Selling Ankle Brace in 2009 2
... RNA Mini Kit allows purification ... cell-free fluid samples. Examples of ... be isolated with this kit ... to, RNA from hepatitis A, ...
The Mago® Plus Automated EIA Analyzer is a fully automated, integrated ELISA system. Together, with immunosimplicity® reagents, the Mago® Plus provides a flexible, integrated solution ...
... computer-enhanced microplate reader with a ... flexible and rapid photometric analysis. ... and reliable photometric measurement of ... shaking before reading) and can ...
The Rapidpoint 400/405 instrument is a point-of-care blood gas analyzer that's fast, easy to operate and reliable....
Medicine Products: